A Review of Clinical Trials in Down Syndrome.

4区 医学 Q3 Medicine
Emily Denne, Marie Moore Channell, Nicole White, Deborah Fidler, Nicole Baumer, Jianhua Wu, Ignacio E Tapia, Tanya Froehlich, Sigan Hartley, Anna J Esbensen
{"title":"A Review of Clinical Trials in Down Syndrome.","authors":"Emily Denne, Marie Moore Channell, Nicole White, Deborah Fidler, Nicole Baumer, Jianhua Wu, Ignacio E Tapia, Tanya Froehlich, Sigan Hartley, Anna J Esbensen","doi":"10.1016/bs.irrdd.2025.09.002","DOIUrl":null,"url":null,"abstract":"<p><p>Down syndrome (DS) is a prevalent neurogenetic condition that impacts thousands of individuals, their families, and their communities each year. Due to the relatively high prevalence of DS and co-occurring conditions associated with this diagnosis, it is increasingly becoming the focus of clinical trials. In an effort to review the scope of interventions for this population across time, we reviewed ClinicalTrials.gov for clinical trials being conducted in DS. The goal was to evaluate the targets of clinical trials with individuals with DS, describe changes with the onset of the INCLUDE project, and identify gaps in clinical trial targets with individuals with DS. Across 138 clinical trials related to DS registered on ClinicalTrials.gov, the following target condition emerged (with some trials targeting more than one condition): motor functioning (n = 46), cognition (n = 24), Alzheimer's disease (n = 17), sleep (n = 12), adaptive daily living skills (n = 11), leukemia (n = 10), communication (n = 7), prenatal (n = 4), dental (n = 3), Attention Deficit Hyperactivity Disorder (n = 3), and other (n = 13; any category with <3 registered trials). Collectively, across these conditions, the number and variety in clinical trials in DS have increased substantially post-INCLUDE. Implications and future directions across each area of research are discussed.</p>","PeriodicalId":44571,"journal":{"name":"International Review of Research in Developmental Disabilities","volume":"69 ","pages":"1-49"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779108/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Review of Research in Developmental Disabilities","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.irrdd.2025.09.002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Down syndrome (DS) is a prevalent neurogenetic condition that impacts thousands of individuals, their families, and their communities each year. Due to the relatively high prevalence of DS and co-occurring conditions associated with this diagnosis, it is increasingly becoming the focus of clinical trials. In an effort to review the scope of interventions for this population across time, we reviewed ClinicalTrials.gov for clinical trials being conducted in DS. The goal was to evaluate the targets of clinical trials with individuals with DS, describe changes with the onset of the INCLUDE project, and identify gaps in clinical trial targets with individuals with DS. Across 138 clinical trials related to DS registered on ClinicalTrials.gov, the following target condition emerged (with some trials targeting more than one condition): motor functioning (n = 46), cognition (n = 24), Alzheimer's disease (n = 17), sleep (n = 12), adaptive daily living skills (n = 11), leukemia (n = 10), communication (n = 7), prenatal (n = 4), dental (n = 3), Attention Deficit Hyperactivity Disorder (n = 3), and other (n = 13; any category with <3 registered trials). Collectively, across these conditions, the number and variety in clinical trials in DS have increased substantially post-INCLUDE. Implications and future directions across each area of research are discussed.

唐氏综合征临床试验综述。
唐氏综合症(DS)是一种普遍的神经遗传疾病,每年影响成千上万的个人、家庭和社区。由于退行性椎体滑移的患病率相对较高以及与此诊断相关的合并症,它越来越成为临床试验的重点。为了回顾这一人群的干预范围,我们在ClinicalTrials.gov网站上查阅了正在进行的DS临床试验。目的是评估DS患者临床试验的目标,描述INCLUDE项目开始时的变化,并确定DS患者临床试验目标的差距。在138个临床试验相关ClinicalTrials.gov DS注册,以下目标条件出现(和一些试验针对多个条件):电动机运转(n = 46),认知(n = 24),阿尔茨海默氏症(n = 17),睡眠(n = 12),自适应日常生活技能(n = 11),白血病(n = 10),通信(n = 7),产前(n = 4),牙科(n = 3),注意缺陷多动障碍(n = 3),和其他(n = 13;任何类别
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
12
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书